Next Article in Journal
Rates, Indications, and Speech Perception Outcomes of Revision Cochlear Implantations
Next Article in Special Issue
Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe
Previous Article in Journal
The Effect of Ejaculatory Abstinence Interval on Sperm Parameters and Clinical Outcome of ART. A Systematic Review of the Literature
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study

Antonio Muro
Moncef Belhassen-García
Juan Luís Muñoz Bellido
Helena Lorenzo Juanes
Belén Vicente
Josué Pendones
José Adserias
Gonzalo Sánchez Hernández
Miguel Rodríguez Rosa
José Luis Vicente Villardón
Javier Burguillo
Javier López Andaluz
Jose Angel Martín Oterino
Francisco Javier García Criado
Fausto Barbero
Ana Isabel Morales
Purificación Galindo Villardón
Rogelio González Sarmiento
2,12 and
on behalf of the DIANCUSAL Team
Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain
Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain
Microbiology & Parasitology Service, University Hospital of Salamanca, 37007 Salamanca, Spain
Department of Biomedical and Diagnostic Sciences, University of Salamanca, 37008 Salamanca, Spain
IT Department, University of Salamanca Foundation (FGUSAL), University of Salamanca, 37008 Salamanca, Spain
Data Processing Center (CPD), University of Salamanca, 37008 Salamanca, Spain
Department of Statistics, University of Salamanca, 37008 Salamanca, Spain
Department of Chemistry-Physics, Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain
Department of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, Spain
Department of Internal Medicine, Faculty of Medicine, University Hospital of Salamanca, 37008 Salamanca, Spain
Toxicology Unit, University of Salamanca, 37008 Salamanca, Spain
Molecular Medicine Unit, Department of Medicine, University of Salamanca, 37008 Salamanca, Spain
Authors to whom correspondence should be addressed.
Membership of the group is provided in Appendix A.
J. Clin. Med. 2021, 10(15), 3214;
Submission received: 17 May 2021 / Revised: 10 July 2021 / Accepted: 15 July 2021 / Published: 21 July 2021
(This article belongs to the Special Issue Epidemiology and Impact of SARS-CoV-2 Vaccines)


Background: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. Objective: The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. Methodology: The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July–October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. Principal findings: A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (p = 0.006). Based on the questionnaire, loss of smell and fever were the symptoms most strongly associated with seropositivity, and 22.6% of seropositive participants were asymptomatic. Social distancing was the most effective hygiene measure (p = 0.0007). There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (p = 0.0000), but not between students who lived in private homes and those who lived in dormitories. IgG antibodies decreased over time in the participants with confirmed self-reported COVID-19 diagnoses. Conclusions: The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures.

1. Introduction

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged that causes the illness designated COVID-19 and that has had devastating socioeconomic and public health consequences [1]. A pandemic was declared by the WHO in March 2020 after rapid human-to-human transmission and the intercontinental spread of the virus. More than 121 million people have been infected worldwide, with more than 3.0 million deaths [2]. In Spain, the first SARS-CoV-2 case was identified on 31 January and was determined to have been imported from Germany. Since then, the number of cases has increased rapidly in the country, and Spain is now one of the European countries most affected by the COVID-19 pandemic [3].
Control measures such as the use of masks, physical distancing, contact tracing and isolation in terms of people who have tested positive have been advised. However, these actions have been variably implemented and have proven insufficient in impeding the spread of COVID-19. Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the pandemic and to predict when herd immunity might be reached [4]. A sero-epidemiological study provides information on the proportion of the population exposed and, if the antibodies are a marker of total or partial immunity, the amount of the population that remains susceptible to the virus. Since there is limited access to diagnostic tests, serological surveys are a valuable tool to assess the extent of the epidemic [5], and they have an advantage over epidemiological surveillance of confirmed COVID-19 cases that captures only a proportion of all infections. Seroprevalence studies have been conducted since the onset of the pandemic, mostly with health workers and the general population [6,7]. A nationwide, population-based sero-epidemiology study called “ENE-COVID” was carried out to analyze the prevalence of SARS-CoV-2 in Spain, showing remarkable differences between higher- and lower-prevalence areas [3].
Few seroprevalence studies have been carried out in academic institutions such as universities, and those that have been carried have been conducted with small cohorts [8,9,10,11,12]. Such studies are needed because university communities (faculty, staff and students) could be expected to be among the groups most exposed to SARS-CoV-2. In April 2020, the World Bank estimated that universities and other tertiary educational institutions were closed in 175 countries and communities and that studies were ended or significantly disrupted due to COVID-19 for more than 220 million post-secondary education students [13]. Spain was one of the countries with the strictest conditions during the first wave (March–April 2020), and leaving home was allowed only for essential needs. All universities were closed, and classes continued online with support from academic services.
The University of Salamanca (USAL) is located in western Spain and has ~30,000 students and over 3000 academic staff. USAL comprises a main campus in the city of Salamanca (40°50′0″ N, 6°0′0″ W) and three smaller campuses in Avila (40°39′15.65″ N, 4°41′46.4″ W), Zamora (41°45′0″ N, 6°0′0″ W) and Bejar (40°23′5″ N, 5°45′43″ W), all of which were assessed in this study. The ratio of students to Salamanca city inhabitants is 1:5, which is higher than that of other cities in Spain. Therefore, the influence of the university community in the spread of the SARS-CoV-2 pandemic in Salamanca could be substantial.
To measure antibodies in the university community, teams of professor and student volunteers from the health sciences faculties of USAL conducted the DIANCUSAL project. The aim was to characterize the university community to provide a basis for the eventual implementation of strategies to mitigate cases of COVID-19 at USAL. Thus, the primary objective was to estimate the prevalence of SARS-CoV-2 antibodies among members of USAL and compare it with that of the general population. The secondary objective was to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity detection among members of the USAL community.

2. Material and Methods

2.1. Study Design and Population

The DIANCUSAL (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) project is an ongoing university population-based cross-sectional study. A total of 33,178 students, professors, and staff at USAL were invited by e-mail to enroll in the study. The participants were volunteers and registered online. The flow chart in Figure 1 indicates the inclusion and exclusion criteria. The participants were enrolled in the current study on 14 July and participated until 30 October 2020.

2.2. Data Collection

The anonymized questionnaire focused on COVID-19 was available online on a website designed specifically for DIANCUSAL, (accessed on 1 June 2020). The completion of the questionnaire was required for participation in the study, and those who did not complete the questionnaire were excluded. The participants were asked questions about their clinical and sociodemographic characteristics, symptoms related to SARS-CoV-2 infection, comorbidities, medication use, behavioral factors, etc. All questions are shown in Supplementary Figure S1.

2.3. Serological Testing

Anti-SARS-CoV-2 antibodies were detected and quantified by using chemiluminescent assays for IgG (LIAISON® SARS-CoV-2 S1/S2 IgG) and IgM (LIAISON® SARS-CoV-2 IgM). LIAISON® SARS-CoV-2 S1/S2 IgG is a quantitative test that specifically identifies antibodies against the S1 and S2 proteins of the SARS-CoV-2 spike, which are responsible for the binding and fusion of the virus to the host cell. The spike protein and its subunits are considered the main antigen targets for neutralizing antibodies. LIAISON® SARS-CoV-2 IgM is a qualitative method that detects IgM antibodies against spike proteins. Both methods were performed using a LIAISON XL analyzer (DiaSorin, Saluggia, Italy). Sensitivity for IgG in patients with time elapsed since diagnosis 5–15 days is 90.7% and for patients with time elapsed since diagnosis >15 days is 97.9%. Specificity for IgG is 99%. Sensitivity for IgM in patients with time elapsed since diagnosis 5–15 days is 91.5% and for patients with time elapsed since diagnosis >15 days is 94%. Specificity for IgM is 99.2%.

2.4. Statistical Analysis

The results were expressed as the absolute value (n) and percentage (%) with 95% CI for categorical variables and as the mean, standard deviation (SD), median, interquartile range (IQR) (Q3-Q1) and range (minimum value, maximum value) for continuous variables. A chi-square (χ2) test was used to compare the associations between categorical variables, such as clinical and demographic variables, and the measured outcome was expressed as the odds ratio (OR) and its 95% CI. Continuous variables were compared with Student’s t-test or the Mann-Whitney test for two groups, depending on whether they had a normal or non-normal distribution. Additionally, we applied the corresponding logistic regression model for multivariate analysis of categorical variables. We considered a statistically significant difference to occur at a p-value < 0.05. Data analysis was performed using SPSS 27 (Statistical Package for the Social Sciences).

2.5. Ethics Statement

All participants enrolled in the study voluntarily, and written informed consent was required for the data to be used for analysis. Neither participation in the study nor results were reported to the participants’ employer. The study protocol was approved by the Ethical Review Board of Complejo Asistencial Universitario de Salamanca (CAUSA, Salamanca Spain CEIMc; code 2020 07 539). The procedures were carried out in accordance with the ethical standards described in the Revised Declaration of Helsinki in 2013. All clinical and epidemiological data were anonymized.

2.6. Role of the Funding Source

The funders facilitated data acquisition but had no role in the study design, data analysis or interpretation, or writing of the manuscript.

3. Results

3.1. Demographic Data

From the 33,178 students, professors and staff of USAL who were invited to take part in the study between 15 July 2020 and 30 October 2020, a total of 8197 (24.71%) participants were finally included (Table 1). Most of the participants were undergraduate students (5093, 62.1%), and most participants were aged 17 to 28 years (68.1%). The most represented group was technicians and administrative officers (1017 of 1210, 84.05%), followed by professors and researchers (1553 of 2300, 67.52%), undergraduate students (5093 of 20,849, 24.43%) and postgraduate students (392 of 4692, 8.35%). The mean age was 31.4 (14.5 SD) years; 66.0% of the participants were female.

3.2. Seroprevalence

Seropositivity for IgM and/or IgG antibodies was found in 676/8197 of the participants, corresponding to 8.25% of the sample (95% CI: 7.65–8.84), with IgM detected in 1.04% (95% CI: 0.82–1.26), IgG detected in 7.98% (95% CI: 7.39–8.57) of participants, and both in only 0.77% (95% CI: 0.58–0.96; 63/8197 participants). The highest seropositivity was found in males aged 17 to 28 years (n = 149, 9.3%, (95% CI: 7.92–10.78)) but no significant differences were found by age or sex. Seroprevalence by sex and age for each of the measured antibodies is presented in Supplementary Figure S2.
Additionally, the percentages of participants who tested positive for IgG, those who tested positive for IgM, and those who tested positive for IgG and/or IgM over time (July-October 2020) are presented in Supplementary Figure S3. Of the participants with a previous confirmed SARS-CoV-2 infection, IgG seroprevalence was 83.3% (95% CI: 66.1–100) in July, suggesting that 16.7% (95% CI: 0–33.9) of these individuals had lost the antibodies since initial infection. Additionally, 69.6% (95% CI: 62.5–76.6) of the participants with previous confirmed infection showed IgG seropositivity in October, meaning 30.4% (95% CI: 23.3–37.5) of these participants had lost the antibodies since initial infection.

3.3. Associations of Academic Factors with Seropositivity

We found statistically significant differences in seropositivity among academic positions (p = 0.020). The highest seropositivity rate occurred in the postgraduate students (9.9% (95% CI: 7.0–12.9)), followed by the undergraduate students (8.9% (95% CI: 8.1–9.7)). The lowest rate was observed in the technicians and administrative officers (6.5% (95% CI: 5.0–8.0)). The seroprevalence in the professors/researchers was 7.3% (95% CI: 6.0–8.6).
Of the cities in which the USAL campuses are located, Salamanca was home to the highest proportion of participants in the study (90.2%). The highest positivity rate was in Avila (10.8% (95% CI: 7.5–14.1)), and the lowest was in Bejar (4.2% (95% CI: 0.6–7.9)). Zamora had a positivity rate of 9.9% (95% CI: 6.8–13.0), and Salamanca had a positivity rate of 8.1% (95% CI: 7.5–8.7) (Figure 2); however, this difference among the cities was not statistically significant (p = 0.082). The seroprevalences of professors and students were compared in each city. Higher seropositivity rates were observed in Salamanca and Zamora, and lower rates were observed in Avila and Bejar.
Seroprevalence was analyzed for each campus in Salamanca city (Figure 2). The largest proportion of participants came from the biomedical campus (24.2%), followed by the social sciences campus (19.1%). The education, social sciences, science and biomedical campuses had seroprevalences over 8%. The highest seroprevalence was found for male students from the education campus (12.5% (95% CI: 3.8–21.2)) and male professors from the biomedical campus (12.6% (95% CI: 7.0–18.2)). Additionally, male professors from the psychology and arts campus and female professors from the geography and history campus had the lowest seroprevalence (0.0%) (Figure 3A).
There were highly significant differences in the positivity rates across the various faculties (p = 0.006) (Figure 3B). We observed the highest seropositivity rate in the nursing and physiotherapy faculty (13.3% (95% CI: 10.1–16.5)), followed by the education faculty (10.6% (95% CI: 8.4–12.8)). The lowest prevalence was observed in the psychology, geography and history, and languages faculties (5.7% (95% CI: 3.6–7.7), 6.1% (95% CI: 2.9–9.2) and 6.5% (95% CI: 4.5–8.5), respectively). Moreover, the highest seropositivity rate was found for male professors from the nursing and physiotherapy faculty (26.7% (95% CI: 4.3–49.1)), while the lowest percentage was found for male professors from the psychology faculty (0.0%).

3.4. Associations of Clinical Factors with Seropositivity

Data comparing seroprevalence by self-reported blood type and BMI are shown in Supplementary Table S1. Most of the participants had A (47.3% (95% CI: 45.9–48.6)) or O (40.3% (95% CI: 39.0–41.7)) blood type, and no significant differences in seropositivity were found among blood types. BMI ranged from 18.5 to 24.9 (67.0% (95% CI: 66.0–68.1)); logistic regression analysis revealed no significant relationship between BMI and seropositivity.
Seroprevalence was also studied according to the self-reported presence of symptoms, diseases and drug prescriptions. Among the 676 seropositive participants, 153 (22.6%) were asymptomatic and 523 (77.4%) were symptomatic. Figure 4A shows ORs for the associations of seropositivity with the main symptoms. Loss of smell (5.3% vs. 54%; OR 20.69 (15.95–26.89)) and fever (5.9% vs. 16%; OR 3.02 (2.45–3.72)) were the symptoms most strongly associated with seropositivity. No significant associations were found between seropositivity rates and the overall frequencies, comorbidities or prescriptions of corticosteroids, inhalers or antihistamines.

3.5. Associations of Lifestyle and Behavioral Factors with Seropositivity

The participants’ smoking status and alcohol consumption were also studied. No significant difference in seropositivity was found between alcohol consumers and non-consumers (8.1% for alcohol consumers vs. 8.3% for non-consumers; OR 0.93 (95% CI: 0.67–1.29)). However, a difference was found between smokers and non-smokers, and interestingly, seropositivity more strongly associated with non-smoking (5.2% for current smokers vs. 8.6% for non-smokers; OR 0.57 (95% CI: 0.42–0.79)).
Seroprevalence according to hygiene measures is presented in Figure 4B. We identified a significantly decreased seroprevalence in people who adopted social distancing (p = 0.0007), but no other major differences. Table 2 shows the association of the type of residence and the numbers of cohabitants and pets with seroprevalence. There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (p = 0.0000). In the student group, there were no differences in seroprevalence between those who lived in private homes and those who lived in dormitories.

4. Discussion

Our cross-sectional study was carried out between June and October 2020 using chemiluminescent assays for antibody detection and a questionnaire. The overall objective of our study was to carry out a comprehensive study of the university community to guide strategies to mitigate possible cases of COVID-19 at USAL for safe reopening in the 2020/2021 academic year. We analyzed the demographic, academic, clinical and lifestyle and behavioral factors associated with COVID-19 in a university sample, with a high participation rate. It was found that (i) the overall seroprevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) was 8.25%—this rate is similar to that in studies of larger communities [14]; (ii) antibody seropositivity decreased over time; (iii) there was a higher seroprevalence in students and professors in health-related campuses and faculties than in other campuses and faculties; (iv) the seroprevalence was similar across campuses, but there were highly significant differences among faculties; (v) asymptomatic status was observed in 22.6% of the seropositive participants and loss of smell was the main symptom associated with antibody detection; and vi) the only hygiene measure associated with lower seroprevalence was social distancing.
Seroprevalence studies are currently being implemented worldwide, as they are considered a valuable tool to reveal the extent of SARS-CoV-2 infection via the estimation of the proportion of the population exposed to the virus. To the best of our knowledge, this is the largest study describing the prevalence of SARS-CoV-2 in an academic population in Europe. The seroprevalence of the university community observed in our study and that previously found for the general population were very similar [14]. However, the USAL seroprevalence rate was higher than the seroprevalence rates of other academic communities, such as the University of Southern California [10] and the University of Pennsylvania [11] in the USA, the University of Athens in Greece [12] and the University of Alicante in Spain (8) (2.6–5.5%) but lower than that of the University of Sergipe in Brazil (22.5%) [9]. These differences could be due to the following: (i) some studies included a smaller number of participants; (ii) the previous studies were carried out exclusively with students; (iii) the serological tests used varied across studies with different levels of sensitivity; and (iv) studies were performed over different periods of time.
One main finding of this study was a difference in seropositivity between students and university staff. The highest rate was found in postgraduate students followed by undergraduate students, and the lowest rate was observed in technicians and administrative officers. Students’ large social networks could be a primary cause of these results. We initially expected that students could be responsible for the spread of infection in our region. However, our results indicate that student communities had exhibited more protective behavior against the spread of the pandemic than other groups.
In addition, while we found that seropositivity did not significantly differ across cities, the highest seroprevalence was found in the participants from Avila, probably due to the proximity of this town to the capital of Spain, Madrid. It is well known that Madrid had a higher seroprevalence in the first wave of the pandemic than other Spanish cities due to the centrifugal spread of the virus [3]. Social factors, such as the population structure and poverty, which were not considered in our study, might also explain the higher prevalence in Avila.
In terms of subject area, our comparison of the seroprevalence across Salamanca campuses showed the highest seropositivity rates for students from the education campus and male professors from the biomedical campus. The first clinical cases detected at USAL were in the education faculty, and the PCR technique was not systematically used to identify students with contact with the index patient, which allowed the infection to spread. In addition, higher seroprevalence was found in professors from biomedical campuses, particularly in the nursing and physiotherapy faculty due to their interactions with hospital environments.
We also investigated the association of clinical and lifestyle factors, such as comorbidities, BMI, blood type, smoking and alcohol consumption, with seropositivity. Previous research has shown that comorbidities occur with SARS-CoV-2 infection in approximately half of inpatients. Hypertension was found to be the most common comorbidity, followed by obesity, diabetes and coronary heart disease [15]. Moreover, in a different study, obesity and adiposity-related diseases were shown to be clearly related to worse disease evolution [16]. In our study, no differences in seroprevalence according to weight (represented as BMI) and groups of diseases consistently linked to the prescription of certain medications were observed. Patients with a smoking history had a higher likelihood of developing more severe symptoms of COVID-19 disease than non-smokers. However, data on whether COVID-19 has a greater incidence in smokers than non-smokers have thus far been contradictory and inconclusive [17]. Surprisingly, our data showed tobacco use to be a protective factor, demonstrating the need for more studies to clarify the role of smoking in the incidence of COVID-19. Interestingly, previous research showed that the ABO blood group was associated with SARS-CoV-2 infection and survival [18]. Group A has been found to be more common, while group O has been found to be less common among infected individuals. Moreover, blood group O has shown lower mortality than the other ABO blood groups. In our study, the ABO blood group did not show any relationship to seroprevalence.
Furthermore, we examined the association of various symptoms with seropositivity. The most common symptoms among young SARS-CoV-2 patients were previously found to involve the ear and nose [19]. In our cohort, which was composed primarily of students, the main clinical manifestation linked with higher seroprevalence was loss of smell. Interestingly, 22.6% of the participants who presented antibody positivity did not report any symptoms. This finding suggests that asymptomatic infection is relatively common in a healthy population. Thus, among asymptomatic individuals, infections could resolve spontaneously without complications, as occurs in other coronavirus infections. Therefore, the rapid identification of asymptomatic individuals is essential to control the spread of infection. Moreover, clinical characteristics could influence the real prevalence of this disease. Additionally, aspects of infection, such as immunity, reinfection and cross-reactivity with human endemic coronavirus, are not yet known [20].
Governments across the world have implemented a wide range of measures to mitigate the spread of SARS-CoV-2 infection, but the optimal non-pharmaceutical strategies are not entirely clear [21]. Our findings highlight differences between adults in the academic community who received positive SARS-CoV-2 test results and those who received negative SARS-CoV-2 test results. Our data showed that among various hygiene measures, such as the use of hydroalcoholic gel, masks and gloves, only social distancing was associated with a significantly decreased seroprevalence. Continued assessment of the activities and exposure of communities, schools and workplaces during reopening is important. Exposure and activities where mask use and social distancing are difficult to maintain, including going to locations that offer on-site eating and drinking, might be important risk factors for SARS-CoV-2 infection. Hence, implementing safe practices to reduce exposure to SARS-CoV-2 during on-site eating and drinking should be considered to protect customers, employees and communities and to slow the spread of COVID-19 [22].
Regarding the place of transmission, our data showed significant differences between participants with and without household exposure to SARS-CoV-2. These results are consistent with other reports suggesting that households are the principal place of transmission [23]. Interestingly, we also noted that in the student group, there were no differences between those who lived in private homes and those who lived in dormitories, which is in contrast to the assumption that colleges would be environments with a higher risk of infection since they are spaces characterized by a greater amount of social interaction.
Seroprevalence over time is the main indicator of the maintenance of specific antibodies against SARS-CoV-2. Our results were similar to those of other studies that showed a decrease in IgG antibodies over time [24]. The epidemiological impact of the decrease in seroprevalence over time in academic communities must be elucidated.
Several limitations of this study must be considered. By design, this study was carried out in a specific population. Thus, the results cannot be extrapolated directly to the general population. The serological tests we used in this study could also be a limitation. However, chemiluminescent assays were shown to have higher sensitivity and specificity rates than other methods [25]. Additionally, data were obtained through a self-report questionnaire completed by the participants. Neither ethnicity nor income data were collected, preventing the analysis of previously demonstrated associations with COVID-19 positivity [26].
In summary, our analysis of more than 8100 USAL community members estimated the exposure of members of this community to SARS-CoV-2, revealing approximately 8% seroprevalence from July–October 2020 and a higher prevalence in students than in university staff. Our findings suggest that there is no need for tailored measures for USAL members who should comply with public health measures, especially the maintenance of social distancing, as well as implement new measures, such as vaccination.

Supplementary Materials

The following are available online at, Figure S1: Questionnaire, Figure S2: Seroprevalence by sex and age group, Figure S3: Seroprevalence according to the time of the serology, Table S1: Seroprevalence of IgG & IgM antibodies according to blood types and Body Mass Index (BMI).

Author Contributions

Conceptualization, A.M., M.B.-G., J.L.M.B., F.J.G.C., F.B., A.I.M., P.G.V. and R.G.S.; methodology, A.M., M.B.-G., J.L.M.B., H.L.J., B.V. and J.P.; software, J.A., G.S.H., M.R.R. and J.L.V.V.; validation, J.A.M.O., F.J.G.C., F.B. and A.I.M.; formal analysis, A.M., M.B.-G., J.L.M.B., M.R.R., J.L.V.V., J.B., P.G.V. and R.G.S.; investigation, A.M., M.B.-G., J.L.M.B., H.L.J., B.V. and DIANCUSAL team; resources, P.G.V. and R.G.S.; data curation, A.M., M.B.-G., J.L.M.B., H.L.J., B.V., J.P., M.R.R., J.L.V.V., J.B. and P.G.V.; writing—original draft preparation, A.M. and M.B.-G.; writing—review and editing, A.M., M.B.-G., J.L.M.B., M.R.R., J.L.V.V. and J.B.; visualization, J.A.; supervision, A.M., J.L.A., B.V., J.A.M.O., F.J.G.C., F.B. and A.I.M. project administration, B.V., J.A., G.S.H. and J.L.-A.; funding acquisition, A.M., P.G.V. and R.G.S. All authors have read and agreed to the published version of the manuscript.


The DIANCUSAL (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) study was funded by a grant from the University of Salamanca (USAL).


We thank the University of Salamanca community and all the volunteers who made this study possible.

Conflicts of Interest

The authors declare they have no conflict of interest.

Appendix A. DIANCUSAL Team (Alphabetical Order)

1. JudyAala
2. ElisaAcosta de la Vega
3. ÁlvaroAguado Muñiz
4. AlbertoAlén Andrés
5. RaquelÁlvarez Lozano
6. Luis ManuelÁlvarez Oricheta
7. RobertoArévalo Pérez
8. ElisabethArias Gómez
9. SamuelBarbero Garrote
10. Beatriz MaríaBermejo Gil
11. EnriqueBlanco Peláez
12. Noelia Bullón
13. EstherCaballero Salvador
14. LauraCabrero
15. Juan CarlosCalderón
16. Rubén Cañizares Sanchez
17. CristinaCarbonell Muñoz
18. ElenaCarnicero Antón
19. RaquelCarnicero Izquierdo
20. Ana Carranza de Frutos
21. Carlos Carrera Tomás
22. LauraCid Mendes
23. Sonia Clavero Sánchez
24. Clara IsabelColino Gandarilla
25. VictoriaCoral Orbes
26. DiegoCotobal García
27. BeatrizCrego Vicente
28. Luisde Alfonso Vazquez
29. Manuel De la Cruz Garcinuño
30. María TeresaDe la Puente Sanz
31. Francisco JavierDerteano Ortiz de Artiñano
32. David Eguiluz López
33. DanielEncinas Sanchez
34. CarlosEstévez Colmenero
35. BegoñaFebrer Sendra
36. HelenaFernández Cabrera
37. AdolfoFernández Sánchez
38. PedroFernández Soto
39. JavierFlores Fraile
40. ManuelFuentes García
41. Andrea Fuentes Gordillo
42. RaúlFuentes Martín
43. Ana IsabelGalán Hernández
44. Juan García-Bernalt Diego
45. LucíaGarcía Aparicio
46. Carlos García Cabezas
47. Vega Garcia Cirilo
48. Raquel Garcia López
49. María de los ÁngelesGarcía Pascua
50. José ÁngelGarcía Pedraza
51. PaulaGarcía Vallés
52. NereaGestoso Uzal
53. MarionaGil Llagostera
54. SoniaGómez Gaspar
55. María IsabelGonzález Flores
56. SusanaGonzález Manzano
57. JoséGordo Gonzalo
58. OscarGorgojo Galindo
59. CarlosGutiérrez Cerrajero
60. RosaHermosa Prieto
61. Reyes Hernández
62. Isabel MaríaHernández de la Fuente
63. Luis ManuelHernández Medina
64. NievesHernández San Antonio
65. SantiagoHerrero González
66. LuisJiménez Jurado
67. RosaJuana Tejera Pérez
68. PaulaLinde Leiva
69. InésLlamas Ramos
70. JulioLópez Abán
71. AmparoLópez Bernus
72. Joaquín FLópez Marcos
73. Noelia López Velázquez
74. AntonioLópez-Valverde Centeno
75. NansiLópez-Valverde Hernández
76. María Lorenzo Santiago
77. PalomaMalmierca Román
78. ElviraManjón Pérez
79. SergioManso Hierro
80. LauraMárquez Arcos
81. Abel JesúsMartel Martel
82. Juan CarlosMartín Corral
83. AlbaMartín del Rey
84. RaquelMartín Fernández
85. ElenaMartín González
86. AlbaMartín Hernández
87. DanielMartín Hidalgo
88. ManuelMartín Morales
89. Ana MaríaMartín Nogueras
90. AnaMartín Suarez
91. AndreaMartín Tomé
92. MaríaMartínez Ferradal
93. AlbaMata Caballero
94. DiegoMatellán Alonso
95. LauraMateos Sánchez
96. Francisco JoséMatos
97. MartaMayo Caballero
98. IsabelMéndez Hernández
99. RobertoMéndez Sánchez
100. Alba MaríaMerino Expósito
101. AdriánMiguélez Martínez
102. EllyMondolis
103. Cristina Mora González
104. CarlosMoreno Dorado
105. RaquelMoreno García
106. MirianMoreno Ramos
107. JorgeMoreno Teniente
108. DanielMuñoz Reyes
109. ElenaNaranjo Bueno
110. VerónicaNavarro Santamaría
111. Cecilia Oliva Mangas
112. PaulaOramas Padrón
113. OlgaOrtuño López
114. MaríaOvejero Sánchez
115. MaríaOviedo Madrid
116. JosuéPendones Ulerio
117. SaraPeral Garrido
118. AnaPerera Gregorio
119. LeyrePérez Hernández
120. LauraPérez Huerga
121. SadePérez López
122. DanielPérez Martin
123. DanielaPérez Ramos
124. FátimaPérez Robledo
125. ÁngelPindado Pérez
126. RocióPindado Saez
127. Carlos RafaelPires Baltazar
128. Olga Pozas Flores
129. IsabelRedero Sanchón
130. María JoséRodrigo Gonzalo
131. ClaraRodrigo Pérez
132. BeatrizRodríguez Alonso
133. CarlosRodríguez Carneiro
134. CeliaRodríguez Tudero
135. MelanieRuiz Navarro
136. EnriqueSánchez Carrasco
137. MyriamSánchez Díaz
138. Ana MSánchez Fernández
139. DanielSánchez González
140. JavierSánchez Montejo
141. CarmenSánchez Sánchez
142. MaríaSánchez Tabernero
143. AliciaSanjosé Crespo
144. GuillermoSantabrígida Oreja
145. LauraSantos Gómez
146. ElenaSantos Hernandez
147. CarmenSantos Marcos
148. MaríaSantos Plaza
149. CristinaSanz Cuesta
150. RosaSepúlveda Correa
151. TeresaSereno Mateos
152. SusanaSudon Pollo
153. Vladut AlexandruTanase Iosub
154. JavierTascón Romero
155. JoséTortosa Cámara
156. ElenaVaras Martín
157. AnaVicente García
158. LidiaVicente Medina
159. LauraVicente Vicente
160. CarmenVieira Lista
161. PaulaVigario Calaco
162. ElenaVillanueva Sánchez
163. CristinaVillaoslada Fuentes
164. AranzazuZarzuelo Castañeda
165. PilarGonzález Arrieta
166. Rosa IsabelSánchez Alonso
167. Mª del PinoMendez Arroyo
168. DavidMartín Fernandez
169. Lauradel Rio Sanz
170. PilarGonzález Barez
171. JesúsMartín González
172. JorgeGarcía Pindado
173. VegaAngulo Sánchez


  1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef]
  2. World Health Organization 2020. Available online: (accessed on 1 May 2021).
  3. Pollan, M.; Perez-Gomez, B.; Pastor-Barriuso, R.; Oteo, J.; Hernán, M.A.; Pérez-Olmeda, M.; Sanmartín, J.L.; Fernández-García, A.; Cruz, I.; Fernández de Larrea, N.; et al. A Population-Based Seroepidemiological Study of SARS-CoV-2 in Spain (ENE-COVID). SSRN Electron. J. 2020, 22, 535–544. [Google Scholar] [CrossRef]
  4. Gudbjartsson, D.F.; Norddahl, G.L.; Melsted, P.; Gunnarsdottir, K.; Holm, H.; Eythorsson, E.; Arnthorsson, A.O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, R.F.; et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 2020, 383, 1724–1734. [Google Scholar] [CrossRef] [PubMed]
  5. Long, Q.-X.; Tang, X.-J.; Shi, Q.-L.; Li, Q.; Deng, H.-J.; Yuan, J.; Hu, J.-L.; Xu, W.; Zhang, Y.; Lv, F.-J.; et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020, 26, 1200–1204. [Google Scholar] [CrossRef] [PubMed]
  6. Iversen, K.; Bundgaard, H.; Hasselbalch, R.B.; Kristensen, J.H.; Nielsen, P.B.; Pries-Heje, M.; Knudsen, A.D.; Christensen, C.E.; Fogh, K.; Norsk, J.B.; et al. Risk of COVID-19 in health-care workers in Denmark: An observational cohort study. Lancet Infect. Dis. 2020, 20, 1401–1408. [Google Scholar] [CrossRef]
  7. Slot, E.; Hogema, B.M.; Reusken, C.B.; Reimerink, J.H.; Molier, M.; Karregat, J.H.; IJlst, J.; Novotný, V.M.; van Lier, R.A.; Zaaijer, H.L. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nat. Commun. 2020, 11, 5744. [Google Scholar] [CrossRef] [PubMed]
  8. Tuells, J.; Egoavil, C.M.; Pardo, M.A.P.; Montagud, A.C.; Montagud, E.; Caballero, P.; Zapater, P.; Puig-Barberá, J.; Hurtado-Sanchez, J.A. Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain). Int. J. Environ. Res. Public Health 2021, 18, 1908. [Google Scholar] [CrossRef] [PubMed]
  9. De Souza Araújo, A.A.; Quintans-Júnior, L.J.; Schimieguel, D.M.; Corrêa, C.B.; de Moura, T.R.; Cavalcante, R.C.M.; Grespan, R.; de Vasconcelos Cerqueira-Meneses, D.; Barreto-Alves, J.A.; Martins-Filho, P.R. Seroprevalence of SARS-CoV-2 antibodies in low-income university students. EXCLI J. 2021, 20, 276–280. [Google Scholar] [CrossRef]
  10. Tilley, K.; Ayvazyan, V.; Martinez, L.; Nanda, N.; Kawaguchi, E.S.; O’Gorman, M.; Conti, D.; Gauderman, W.J.; Orman, S.V. A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population. J. Adolesc. Health 2020, 67, 763–768. [Google Scholar] [CrossRef]
  11. Arnold, C.R.K.; Srinivasan, S.; Herzog, C.M.; Gontu, A.; Bharti, N.; Small, M.; Rogers, C.J.; Schade, M.M.; Kuchipudi, S.V.; Kapur, V.; et al. SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members. medRxiv 2021. [Google Scholar] [CrossRef]
  12. Tsitsilonis, O.E.; Paraskevis, D.; Lianidou, E.; Pierros, V.; Akalestos, A.; Kastritis, E.; Moutsatsou, P.; Scorilas, A.; Sphicopoulos, T.; Terpos, E.; et al. Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life 2020, 10, 214. [Google Scholar] [CrossRef]
  13. World Bank Group. The COVID-19 Crisis Reponse: Supporting Tertiary Education for Continuity, Adaptation, and Innovation; World Bank: Washington, DC, USA, 2020. [Google Scholar]
  14. Rostami, A.; Sepidarkish, M.; Leeflang, M.; Riahi, S.M.; Shiadeh, M.N.; Esfandyari, S.; Mokdad, A.H.; Hotez, P.J.; Gasser, R.B. SARS-CoV-2 seroprevalence worldwide: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2020, 27, 331–340. [Google Scholar] [CrossRef]
  15. Zhou, Y.; Chi, J.; Lv, W.; Wang, Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab. Res. Rev. 2021, 37, e3377. [Google Scholar] [CrossRef]
  16. Cornejo-Pareja, I.M.; Gómez-Pérez, A.M.; Fernández-García, J.C.; Millan, R.B.S.; Luque, A.A.; Hollanda, A.; Jiménez, A.; Jimenez-Murcia, S.; Munguia, L.; Ortega, E.; et al. Coronavirus disease 2019 (COVID-19) and obesity. Impact of obesity and its main comorbidities in the evolution of the disease. Eur. Eat. Disord. Rev. 2020, 28, 799–815. [Google Scholar] [CrossRef]
  17. Shastri, M.D.; Shukla, S.D.; Chong, W.C.; Kc, R.; Dua, K.; Patel, R.P.; Peterson, G.M.; O’Toole, R.F. Smoking and COVID-19: What we know so far. Respir. Med. 2020, 176, 106237. [Google Scholar] [CrossRef] [PubMed]
  18. Zhao, J.; Yang, Y.; Huang, H.; Li, D.; Gu, D.; Lu, X.; Zhang, Z.; Liu, L.; Liu, T.; Liu, Y.; et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. medRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
  19. Lechien, J.R.; Chiesa-Estomba, C.M.; Place, S.; Laethem, Y.V.; Cabaraux, P.; Mat, Q.; Huet, K.; Plzak, J.; Horoi, M.; Hans, S.; et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J. Intern. Med. 2020, 288, 335–344. [Google Scholar] [CrossRef]
  20. Kontou, P.I.; Braliou, G.G.; Dimou, N.L.; Nikolopoulos, G.; Bagos, P.G. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics 2020, 10, 319. [Google Scholar] [CrossRef]
  21. Brauner, J.M.; Mindermann, S.; Sharma, M.; Johnston, D.; Salvatier, J.; Gavenčiak, T.; Stephenson, A.B.; Leech, G.; Altman, G.; Mikulik, V.; et al. Inferring the effectiveness of government interventions against COVID-19. Science 2021, 371, eabd9338. [Google Scholar] [CrossRef]
  22. Fisher, K.A.; Tenforde, M.W.; Feldstein, L.R.; Lindsell, C.J.; Shapiro, N.I.; Files, D.C.; Gibbs, K.W.; Erickson, H.L.; Prekker, M.E.; Steingrub, J.S.; et al. Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities—United States, July 2020. Morb. Mortal. Wkly. Rep. 2020, 69, 1258–1264. [Google Scholar] [CrossRef]
  23. Madewell, Z.J.; Yang, Y.; Longini, I.M.; Halloran, M.E.; Dean, N.E. Household Transmission of SARS-CoV-2. JAMA Netw. Open 2020, 3, e2031756. [Google Scholar] [CrossRef] [PubMed]
  24. Figueiredo-Campos, P.; Blankenhaus, B.; Mota, C.; Gomes, A.; Serrano, M.; Ariotti, S.; Costa, C.; Nunes-Cabaço, H.; Mendes, A.M.; Gaspar, P.; et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur. J. Immunol. 2020, 50, 2025–2040. [Google Scholar] [CrossRef] [PubMed]
  25. Lijia, S.; Lihong, S.; Huabin, W.; Xiaoping, X.; Xiaodong, L.; Yixuan, Z.; Pin, H.; Yina, X.; Xiaoyun, S.; Junqi, W. Serological chemiluminescence immunoassay for the diagnosis of SARS-CoV-2 infection. J. Clin. Lab. Anal. 2020, 34, e23466. [Google Scholar] [CrossRef]
  26. Hooper, M.W.; Nápoles, A.M.; Pérez-Stable, E.J. COVID-19 and Racial/Ethnic Disparities. JAMA 2020, 323, 2466–2467. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Participant flowchart through the recruitment process with eligibility screening, questionnaire completion and testing.
Figure 1. Participant flowchart through the recruitment process with eligibility screening, questionnaire completion and testing.
Jcm 10 03214 g001
Figure 2. Seroprevalence of University of Salamanca: (A) main towns and (B) Salamanca city campus.
Figure 2. Seroprevalence of University of Salamanca: (A) main towns and (B) Salamanca city campus.
Jcm 10 03214 g002
Figure 3. Seroprevalence in University of Salamanca Campus: (A) Faculties in Salamanca city, (B) distribution according sex and position.
Figure 3. Seroprevalence in University of Salamanca Campus: (A) Faculties in Salamanca city, (B) distribution according sex and position.
Jcm 10 03214 g003
Figure 4. Adjusted odds-ratio and 95% confidence intervals for community exposure associated with main symptoms (A) and hygiene measures (B) with COVID-19. * p < 0.05. NS: Non-significant.
Figure 4. Adjusted odds-ratio and 95% confidence intervals for community exposure associated with main symptoms (A) and hygiene measures (B) with COVID-19. * p < 0.05. NS: Non-significant.
Jcm 10 03214 g004
Table 1. Main data according to the different demographic variables selected: age, sex, categories, location campus and faculty.
Table 1. Main data according to the different demographic variables selected: age, sex, categories, location campus and faculty.
Variablesn = 8197 (%)
Mean ± SD; years31.4 ± 14.5
Population17–28 5503 (68.1%)
29–39486 (6.0%)
40–49606 (7.5%)
50–591039 (12.9%)
60–76441 (5.5%)
Male2709 (34.0%)
Female5248 (66.0%)
StudentsUndergraduate5093 (62.1%)
Postgraduate (Master and PhD)392 (4.8%)
Professors1553 (18.9%)
Technicians and Administrative Officers1017 (12.4%)
Others142 (1.7%)
Salamanca University Campus Map
Salamanca7390 (90.2%)
Zamora355 (4.3%)
Avila334 (4.1%)
Bejar118 (1.4%)
Salamanca University Campus
Agriculture and Environment160 (2.2%)
Biomedical1791 (24.2%)
Education456 (6.2%)
Geography and History215 (2.9%)
Language601 (8.1%)
Psychology and Arts580 (7.8%)
Science687 (9.3%)
Social Sciences1408 (19.1%)
Others1492 (20.2%)
Table 2. Seroprevalence relationship with dwelling and exposure.
Table 2. Seroprevalence relationship with dwelling and exposure.
Dwelling and Exposuren = 7034 (%)Seropositivity
n (%)p-Value
ResidenceProfessors1549 (22.0%)114 (7.4%)0.133
Student private house5039 (71.6%)449 (8.9%)
Student colleges446 (6.3%)42 (9.4%)
Life with animalsYes1867 (22.8%)138 (7.4%)0.127
No6330 (77.2%)538 (8.5%)
ExposureHousehold637 (8.0%)189 (29.7%)0.000
No household7049 (88.2%)436 (6.2%)
Not know302 (3.8%)31 (10.3%)
Household ExposureColleges38 (6.0%)13 (34.2%)0.583
Private house599 (94.0%)176 (29.4%)
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Muro, A.; Belhassen-García, M.; Muñoz Bellido, J.L.; Lorenzo Juanes, H.; Vicente, B.; Pendones, J.; Adserias, J.; Sánchez Hernández, G.; Rodríguez Rosa, M.; Vicente Villardón, J.L.; et al. Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study. J. Clin. Med. 2021, 10, 3214.

AMA Style

Muro A, Belhassen-García M, Muñoz Bellido JL, Lorenzo Juanes H, Vicente B, Pendones J, Adserias J, Sánchez Hernández G, Rodríguez Rosa M, Vicente Villardón JL, et al. Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study. Journal of Clinical Medicine. 2021; 10(15):3214.

Chicago/Turabian Style

Muro, Antonio, Moncef Belhassen-García, Juan Luís Muñoz Bellido, Helena Lorenzo Juanes, Belén Vicente, Josué Pendones, José Adserias, Gonzalo Sánchez Hernández, Miguel Rodríguez Rosa, José Luis Vicente Villardón, and et al. 2021. "Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study" Journal of Clinical Medicine 10, no. 15: 3214.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop